An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Completed · Phase 3

Conditions studied: Type 2 Diabetes

In brief

The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any pharmacological treatment for diabetes, when compared to initial treatment with monotherapy dapagliflozin or metformin XR. The safety of this treatment will also be studied

Key facts

Study ID
NCT00643851
Run by
AstraZeneca
People needed
994
Starts
2008-06-01
Expected to finish
2009-08-01
Last updated by the study team
2023-01-30

Who can join

Age: 18 and older, up to 77. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.